Juergen Engel to become president and ceo of Æterna Zentaris

Published: 15-Aug-2008
Recruitment

A leading professor of endocrinology and oncology has been named new president and ceo of global biopharma company Æterna Zentaris.


A leading professor of endocrinology and oncology has been named new president and ceo of global biopharma company Æterna Zentaris.

The company, which is based in Quebec, Canada, has confirmed that from 1 September, has confirmed that Professor Juergen Engel will succeed Juergen Ernst, who had been acting as interim president and ceo since April 2008.

Engel is currently executive vice president and chief scientific officer of Æterna Zentaris.

"As a seasoned executive for many years at Æterna Zentaris, Engel has gained a deep knowledge of the Company's activities at all levels. We feel that his extensive expertise in drug development and commercialisation as well as in strategic partnerships, make him the ideal person to lead the company," said Ernst.

Engel added: "I am thrilled with this new challenge and will continue to dedicate all efforts to the successful development of our deep pipeline, especially the ongoing pivotal Phase 3 program in benign prostatic hyperplasia with our lead compound, cetrorelix."

See more

You may also like

Recruitment

Rentschler Biopharma continues hiring at global sites

Read more
During 2021, the company has hired more than 300 employees across all business functions with a strong focus on production and laboratory personnel

Trending Articles

  1. hard to swallow...
  2. People on the Move US biotechnology company <i>La Jolla Pharmaceutical</i> has promoted <b>Gail Sloan</b> to vice president of finance, controller and secretary. Sloan has previously worked with Affymax Research Institute and Ernst & Young.
  3. Bioprogress appoint new position and restructure board <p>BioProgress, the speciality pharmaceutical and healthcare company, has announced the creation of a new executive operational board, and the appointment of Keith Hemming, as head of operations in a new position within the management team of the company.</p>
  4. Drug formulation and delivery expert Dr Joseph Reo appointed as Catalent’s Director of Global Scientific Affairs Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced the appointment of Dr Joseph (Joe) Reo to the role of Director of Global Scientific Affairs
  5. People on the move

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Recruitment

Rentschler Biopharma continues hiring at global sites

During 2021, the company has hired more than 300 employees across all business functions with a strong focus on production and laboratory personnel
Recruitment

Vetter Pharma invests $4.1m in Ravensburg training facility

The centre opened on September 14, with a small celebration held for management, training management and trainees.
Recruitment

Does pharma have a problem with inclusivity and innovation?

As we’ve seen only too clearly in recent weeks, the pharmaceutical industry is of paramount importance to the global economy and society. The collaboration regarding the COVID-19 pandemic is an example of the sector at its best, reports Stephen Frost, Founder, Frost Included
Recruitment

Cell Mogrify undergoes period of change

A cash injection and change in leadership gives momentum to the cell therapy company for direct cellular conversion platform
Recruitment

Novartis scoops Top Employer award

Novartis UK and its subsidiary, Sandoz, have been certified as ‘Top Employers’ of 2019 by Top Employers Institute
Recruitment

Retention, not just recruitment

Six ways to protect your company from the skills crisis
Recruitment

Particle Testing Authority (PTA) boosts company's thermal analysis capabilities

Particle Testing Authority (PTA), a division of Micromeritics Instrument Corporation, now has expanded thermal analysis capabilities with addition of Bryan Shaw to its team
Subscribe now